Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs

Summit Therapeutics ( (SMMT) ) has shared an announcement.

On February 23, 2026, Summit Therapeutics reported its fourth-quarter and full-year 2025 results, highlighting rapid advancement of ivonescimab across a broad Phase III oncology program and multiple collaborations. The company’s global HARMONi-3 Phase III study in first-line metastatic NSCLC has completed screening for the squamous cohort, with an interim progression-free survival analysis planned in the second quarter of 2026 and final PFS data expected in the second half of 2026, while enrollment of the non-squamous cohort is slated to complete in the second half of 2026 with final PFS analysis anticipated in the first half of 2027.

Summit detailed the forthcoming GORTEC-sponsored Phase III ILLUMINE trial in PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma, expected to begin enrolling roughly 780 patients in early second quarter 2026 to compare ivonescimab-based regimens against pembrolizumab monotherapy. The company also noted that the U.S. FDA accepted its BLA for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-squamous NSCLC, setting a PDUFA goal date of November 14, 2026, underscoring a potential near-term commercialization pathway that could reshape its revenue profile if approved.

Operationally, Summit is expanding ivonescimab’s reach through a June 2025 clinical collaboration with Revolution Medicines, where patient enrollment began in first quarter 2026 to test combinations with RAS(ON) inhibitors in RAS-mutant solid tumors, and a January 2026 collaboration with GSK to evaluate combinations with B7-H3 antibody risvutatug rezetecan starting mid-2026. The company continues to support over 60 investigator-sponsored trials, including at major cancer centers such as MD Anderson, Memorial Sloan Kettering, and Dana-Farber, positioning ivonescimab as a broadly investigated backbone therapy in solid tumors.

Financially, Summit ended 2025 with $713.4 million in cash, cash equivalents, and short-term investments, up from $412.3 million a year earlier, providing substantial runway for its late-stage pipeline. GAAP operating expenses surged to $1.09 billion in 2025 from $226.0 million in 2024, driven largely by $681.4 million of additional stock-based compensation tied to performance-based option modifications, while non-GAAP operating expenses nearly doubled to $362.0 million, reflecting substantial clinical expansion and escalating development costs for ivonescimab.

The most recent analyst rating on (SMMT) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.

Spark’s Take on SMMT Stock

According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.

The score is held back primarily by weak financial performance (large and worsening losses with accelerating cash burn) and bearish technicals (below all major moving averages with negative momentum). Offsetting these are strong clinical/regulatory catalysts highlighted in the earnings call and corporate events (BLA submission/acceptance and positive Phase III results), while valuation is difficult to assess given ongoing losses and no dividend.

To see Spark’s full report on SMMT stock, click here.

More about Summit Therapeutics

Summit Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing ivonescimab (SMT112), a potentially first-in-class bispecific antibody that combines PD-1 immune checkpoint inhibition with VEGF-driven anti-angiogenesis in a single molecule. The company is targeting major solid tumor indications, notably non-small cell lung cancer and colorectal cancer, with global multiregional Phase III trials and broad geographic commercialization rights outside China, while partner Akeso leads development in China across multiple tumor types.

Average Trading Volume: 2,648,499

Technical Sentiment Signal: Hold

Current Market Cap: $11.82B

For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.